William Blair Has Pessimistic Outlook of CRL Q4 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at William Blair cut their Q4 2024 earnings estimates for shares of Charles River Laboratories International in a note issued to investors on Thursday, November 7th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings of $2.46 per share for the quarter, down from their prior estimate of $2.57. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.20 per share. William Blair also issued estimates for Charles River Laboratories International’s Q1 2025 earnings at $2.41 EPS, Q4 2025 earnings at $2.85 EPS and FY2025 earnings at $10.59 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $2.72 earnings per share.

Other equities research analysts have also issued research reports about the company. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Bank of America downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. The Goldman Sachs Group reduced their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Finally, Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $217.54.

Charles River Laboratories International Stock Up 2.5 %

CRL stock opened at $220.69 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.21. The stock has a market capitalization of $11.29 billion, a price-to-earnings ratio of 27.62, a PEG ratio of 5.80 and a beta of 1.38. Charles River Laboratories International has a fifty-two week low of $168.24 and a fifty-two week high of $275.00. The business’s fifty day moving average price is $194.37 and its two-hundred day moving average price is $208.00.

Charles River Laboratories International declared that its board has initiated a stock repurchase plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Charles River Laboratories International

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Boston Trust Walden Corp grew its stake in Charles River Laboratories International by 2.8% in the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock valued at $41,381,000 after acquiring an additional 5,375 shares during the period. State Board of Administration of Florida Retirement System grew its stake in Charles River Laboratories International by 5.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock worth $15,401,000 after purchasing an additional 2,739 shares in the last quarter. Natixis purchased a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $1,058,000. Tidal Investments LLC raised its holdings in shares of Charles River Laboratories International by 99.8% in the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock valued at $1,435,000 after purchasing an additional 2,646 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in Charles River Laboratories International by 2,733.4% in the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after buying an additional 238,766 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).